Rock Springs Capital Management LP Boosts Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Rock Springs Capital Management LP raised its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 1.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,080,963 shares of the company’s stock after purchasing an additional 17,053 shares during the period. Rock Springs Capital Management LP owned 1.89% of Structure Therapeutics worth $29,316,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Geode Capital Management LLC grew its holdings in Structure Therapeutics by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock valued at $1,985,000 after buying an additional 312 shares during the last quarter. ANTIPODES PARTNERS Ltd increased its position in Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares in the last quarter. LPL Financial LLC raised its stake in Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company’s stock valued at $311,000 after purchasing an additional 646 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in Structure Therapeutics by 12.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company’s stock valued at $201,000 after purchasing an additional 843 shares in the last quarter. Finally, Money Concepts Capital Corp boosted its stake in shares of Structure Therapeutics by 4.2% during the 4th quarter. Money Concepts Capital Corp now owns 21,031 shares of the company’s stock worth $570,000 after purchasing an additional 848 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GPCR has been the topic of several recent analyst reports. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Up 17.4 %

GPCR stock opened at $21.76 on Monday. Structure Therapeutics Inc. has a 52 week low of $13.22 and a 52 week high of $62.74. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -29.41 and a beta of -1.35. The business has a fifty day simple moving average of $20.23 and a 200-day simple moving average of $28.31.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.